IP Library Granted Patent US 7,417,110
Granted Patent B2
US 7,417,110 · App. 10/500,565 · Granted Aug 26, 2008

Biodegradable polyphosphoramidates for controlled release of bioactive substances

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,417,110
App. No.
10/500,565
Granted
Aug 26, 2008
Kind
B2
Abstract

The present invention is directed to a series of new polycationic biodegradable polyphosphoramidates. Process for making the polymers, compositions containing these polymers and bioactive ligands to enhance the cellular uptake ad intracellular trafficking, articles and methods for delivery of drugs and genes using these polymers are described. A gene delivery system based on these polymers is prepared by complex coacervation of nucleic acid (DNA or RNA) with polymers. Targeting ligands and molecules that could facilitate gene transfer can be conjugated to polymers to achieve selective and enhanced gene delivery. The current invention also provides a complex composition with buffering capacity.

Claims (27)

1. A water soluble and positively charged biodegradable polyphosphoramidate that is capable of forming a complex with negatively charged bioactive macromolecules in aqueous solutions and comprises the recurring monomeric unit shown in Formula I:

wherein

R 1 is a divalent aliphatic organic moiety;

R 2 and R 3 are each independently selected from the group consisting of hydrogen, alkyl, aryl heteroaryl, heteroalicyclic, cycloalkyl, aralkyl, and cycloalkylalkyl groups;

each non-hydrogen occurrence of R 2 and R 3 is substituted with one or more positively charged groups; and

n is from 20 to 2,000;

wherein when R 1 is —(CH 2 ) a — and one of R 2 and R 3 is hydrogen, the other of R 3 and R 2 is selected from the group consisting of hydrogen, aryl, heteroaryl, heteroalicylcic, cycloalkyl, aralkyl, and cycloalkylaklyl,

wherein a ranges from 2 to 6.

2. A positively charged biodegradable polyphosphoramidate of claim 1 , wherein the biodegradable polyphosphoramidate has between about 20 and about 2,000 phosphoramidate groups.

3. A positively charged biodegradable polyphosphoramidate of claim 2 , wherein one or more of R 1 , R 2 , or R 3 is substituted with one or more groups capable of facilitating intracellular delivery of a negatively charged bioactive macromolecules, selected from the group consisting of lysosomalytic agent, an amphiphilic peptide, and a steroid derivative.

4. A positively charged biodegradable polyphosphoramidate of claim 3 , wherein the group capable of facilitating intracellular delivery of negatively charged bioactive macromolecules is a cholesteryl group.

5. A positively charged biodegradable polyphosphoramidate of claim 1 , wherein R 1 is defined in Formula II:

wherein each occurrence of R 4 and R 5 are independently selected from the group consisting of hydrogen and alkyl groups; and

q is 2 to 4.

6. A composition comprising a water soluble and positively charged biodegradable polyphosphoramidate that is capable of forming a complex with negatively charged bioactive macromolecules in aqueous solutions having a recurring monomeric unit shown in Formula III:

wherein

R 1 is a divalent aliphatic organic moiety;

R 2 and R 3 are each independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, heteroalicyclic, cycloalkyl, aralkyl, and cycloalkylalkyl groups;

each non-hydrogen occurrence of R 2 and R 3 is substituted with one or more positively charged groups;

R 4 and R 5 are independently selected from the group consisting of alkyl, cycloalkyl, alkoxy, aryl, heteroaryl, heteroalicycic, aralkyl, and a steroid derivative;

q is from about 1 to about 5; and

n is from about 20 to about 2,000.

7. The composition of claim 1 , wherein the biodegradable polyphosphoramidate has between about 20 and about 2,000 phosphoramidate groups.

8. The composition of claim 1 , wherein non-hydrogen occurrences R 2 and R 3 are substituted with one or more charged groups selected from the group consisting of primary amine, secondary amine, tertiary amine, quaternary amine, and imidazoyl.

9. The composition of claim 2 , wherein one or more of R 1, R 2, or R 3 is substituted with one or more groups capable of facilitating intracellular delivery of a negatively charged bioactive macromolecules, selected from the group consisting of lysosomalytic agent, an amphiphiic peptide, and a steroid derivative.

10. The composition of claim 3 , wherein the group capable of facilitating intracellular delivery of negatively charged bioactive macromolecules is a cholesterol group.

11. The positively charged biodegradable polyphosphoramidate of claim 1 , wherein non-hydrogen occurrences R 2 and R 3 are substituted with one or more charged groups selected from the group consisting of primary amine, secondary amine, tertiary amine, quaternary amine and imidazoyl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2005
From: WANG, JUN; MAO, HAI-QUAN; LEONG, KAM WENG
To: JOHNS HOPKINS SINGAPORE PTE LTD.
Reel/Frame 015545/0782 →
Continuity (2)
Provisional Application 6029083300 · May 14, 2001
Related Publication 20050119450A1 · Jun 2, 2005